Local High-Dose Radiotherapy Induces Systemic Immunomodulating Effects of Potential Therapeutic Relevance in Oligometastatic Breast Cancer

Local High-Dose Radiotherapy Induces Systemic Immunomodulating Effects of Potential Therapeutic Relevance in Oligometastatic Breast Cancer

Local irradiation of cancer through radiotherapy can induce spontaneous regression of non-directly irradiated lesions, suggesting the involvement of systemic antitumor immune responses. In oligometastatic breast cancer (BC) patients, the use of stereotactic body radiotherapy (SBRT) favors the local...

Full description

Bibliographic Details
Main Authors:	Elena Muraro, Carlo Furlan, Michele Avanzo, Debora Martorelli, Elisa Comaro, Aurora Rizzo, Damiana A. Fae’, Massimiliano Berretta, Loredana Militello, Alessandro Del Conte, Simon Spazzapan, Riccardo Dolcetti, Marco Trovo’
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2017-11-01
Series:	Frontiers in Immunology
Subjects:	oligometastatic breast cancer stereotactic body radiotherapy antitumor T cell responses immunomodulation radiotherapy immunogenicity
Online Access:	http://journal.frontiersin.org/article/10.3389/fimmu.2017.01476/full

Similar Items

Low-Burden Oligometastatic Disease of the Lung Treated with Robotic Stereotactic Ablative Radiotherapy: A Retrospective Study
by: Anna Zygogianni, et al.
Published: (2025-02-01)

Outcome of lung oligometastatic patients treated with stereotactic body irradiation
by: Guillaume Virbel, et al.
Published: (2022-07-01)

Stereotactic body radiotherapy for recurrent and oligometastatic soft tissue sarcoma
by: Xiao-Yao Feng, et al.
Published: (2022-09-01)

Metastases-directed local therapies (MDT) beyond genuine oligometastatic disease (OMD): Indications, endpoints and the role of imaging
by: Joachim Widder, et al.
Published: (2024-03-01)

Lower fluorodeoxyglucose positron emission tomography maximum standardized uptake value may show a better response to stereotactic body radiotherapy of adrenals in oligometastatic disease
by: Kiril Zhelev, et al.
Published: (2024-02-01)

Highlights on the Management of Oligometastatic Disease
by: Salem M. Alshehri, et al.
Published: (2020-02-01)

Radiotherapist’s View on the Role of Current Diagnostic Imaging in Pre-Radiation Preparation of Patients with Oligometastatic Disease for Conformal Radiotherapy
by: G. A. Panshin, et al.
Published: (2024-10-01)

Stereotactic Body Radiotherapy for Oligometastatic Disease in Non-small Cell Lung Cancer
by: Caryn Wujanto, et al.
Published: (2019-11-01)

REPeated mAgnetic resonance Image-guided stereotactic body Radiotherapy (MRIg-reSBRT) for oligometastatic patients: REPAIR, a mono-institutional retrospective study
by: Giuditta Chiloiro, et al.
Published: (2024-04-01)

Dosimetric Evaluation of the Inter-Fraction Motion of Organs at Risk in SBRT for Nodal Oligometastatic Prostate Cancer
by: Francesco La Fauci, et al.
Published: (2022-10-01)

SABR for oligometastatic renal cell carcinoma
by: Chang David, et al.
Published: (2024-03-01)

COMPARISON OF THE EFFECTIVENESS OF STEREOTACTIC RADIOSURGERY FOR SPINAL OLIGOMETASTATIC DISEASE WITH SURGICAL AND CONVENTIONAL EXTERNAL BEAM RADIOTHERAPY DETERMINED BY LOCAL CONTROL, OVERALL SURVIVAL, PAIN RESPONSE AND TOXICITIES: A SYSTEMATIC REVIEW.
by: Priyanshu Saha, et al.
Published: (2020-06-01)

Proton Radiotherapy for Patients With Oligometastatic Breast Cancer Involving the Sternum
by: Andrew Johnson, BS, et al.
Published: (2021-11-01)

Efficacy and Safety of Local Radiotherapy to All Oligometastatic Sites in Elderly Patients with Metachronous Oligometastatic Cancers After Initial Treatment for the Primary Tumor
by: Hu X, et al.
Published: (2021-12-01)

13-year survival oligometastatic Merkel cell carcinoma: a case report
by: I. Trampetti, et al.
Published: (2024-09-01)

Radiotherapy of oligometastatic prostate cancer: a systematic review
by: Paul Rogowski, et al.
Published: (2021-03-01)

Role of Consolidative Stereotactic Body Radiation Therapy in Oligoresistant/Oligoprogressive Pulmonary Parenchymal Metastases
by: Berber T, et al.
Published: (2022-08-01)

Stereotactic body radiotherapy as metastasis-directed therapy in oligometastatic prostate cancer: a systematic review and meta-analysis of randomized controlled trials
by: Astrid E. Persson, et al.
Published: (2024-12-01)

The Importance of Radiation Planning Guidelines in Spinal Stereotactic Body Radiotherapy
by: Ory Haisraely, et al.
Published: (2024-06-01)

Safety and Efficacy of Concurrent or Sequential Radiotherapy Plus (PD-1) Inhibitors in Oligometastatic Esophageal Cancer
by: Duan Y, et al.
Published: (2023-01-01)

Survival Outcomes and Pattern of Relapse After SABR for Oligometastatic Prostate Cancer
by: Carole Mercier, et al.
Published: (2022-04-01)

Robotic Stereotactic Body Radiation Therapy for Oligometastatic Liver Metastases: A Systematic Review of the Literature and Evidence Quality Assessment
by: Ilektra Kyrochristou, et al.
Published: (2024-05-01)

Stratification of Oligometastatic Prostate Cancer Patients by Liquid Biopsy: Clinical Insights from a Pilot Study
by: Antonella Colosini, et al.
Published: (2022-06-01)

Oligometastatic head and neck cancer: Which patients benefit from radical local treatment of all tumour sites?
by: Thomas Weissmann, et al.
Published: (2021-03-01)

A predictive model of polymetastatic disease from a multicenter large retrospectIve database on colorectal lung metastases treated with stereotactic ablative radiotherapy: The RED LaIT-SABR study
by: Luca Nicosia, et al.
Published: (2023-03-01)

Stereotactic body radiotherapy to defer systemic therapy in patients with oligorecurrent disease
by: Jonas Willmann, et al.
Published: (2022-11-01)

Stereotactic Body Radiotherapy for Lymph-Nodal Oligometastatic Prostate Cancer: A Multicenter Retrospective Experience
by: Francesco Cuccia, et al.
Published: (2023-08-01)

Endoscopic nodal staging in oligometastatic non-small cell lung cancer (NSCLC) being treated with stereotactic ablative radiotherapy (ENDO-SABR)
by: Inderdeep Dhaliwal, et al.
Published: (2022-04-01)

Consolidatory ablative stereotactic body radiation therapy after induction chemotherapy for unresectable pancreatic cancer: A single center experience
by: Hye In Lee, et al.
Published: (2022-11-01)

Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease
by: Neil R. Parikh, et al.
Published: (2019-04-01)

Oligometastatic cancer
by: Ivica Ratoša, et al.
Published: (2022-11-01)

The role of local and systemic control methods in the treatment of oligometastatic breast cancer, taking into account biological subtypes (literature review)
by: T. I. Sevostyanova, et al.
Published: (2024-11-01)

Stereotactic body radiotherapy takes on Lung Oligometastases: Latest breakthroughs
by: Xin Liu, et al.
Published: (2024-06-01)

Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5
by: Robert Olson, et al.
Published: (2018-10-01)

A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS)
by: Hamza Hasan, et al.
Published: (2020-06-01)

Stereotactic ablative radiotherapy for the comprehensive treatment of 1–3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial
by: Robert Olson, et al.
Published: (2020-05-01)

Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial
by: David A. Palma, et al.
Published: (2019-08-01)

Stereotactic body radiotherapy improves the survival of patients with oligometastatic non‐small cell lung cancer
by: Wen Ouyang, et al.
Published: (2019-08-01)

Radiotherapy(R) Integration(I) Strategy for Small(S)-Cell Lung Cancer in Extensive(E) Stage (RISE) with up to 10 metastases- a study protocol of a randomized phase II trial
by: Łukasz Kuncman, et al.
Published: (2025-01-01)

Stereotactic Radiosurgery/Radiotherapy: A Historical Review
by: Mansoureh Nabavi, et al.
Published: (2014-04-01)